



Empowering Antibiotics In The Amr Landscape: Insights From Dendrimer Conjugation In Ali Systems

Martinenghi, Laura Daniela; Van den Nobelen, Tim; Christensen, Jørn Bolstad; Molin, Søren; Johansen, Helle Krogh; Leisner, Jørgen J.

Published in:
The Danish Microbiological Society Annual Congress 2023

Publication date:
2023

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
Martinenghi, L. D., Van den Nobelen, T., Christensen, J. B., Molin, S., Johansen, H. K., & Leisner, J. J. (2023). Empowering Antibiotics In The Amr Landscape: Insights From Dendrimer Conjugation In Ali Systems. In *The Danish Microbiological Society Annual Congress 2023: Abstract book* (pp. 58-58). Article 56 Danish Microbiological Society.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

POSTER PRESENTATIONS

[56] EMPOWERING ANTIBIOTICS IN THE AMR LANDSCAPE: INSIGHTS FROM DENDRIMER CONJUGATION IN ALI SYSTEMS

Laura Daniela Martinenghi*,¹, Tim Van den Nobelen,², Jørn Bolstad Christensen,³, Søren Molin,⁴, Helle Krogh Johansen,⁵, Jørgen Leisner,⁶

¹ Copenhagen University, Faculty of Health and Medical Science- Department of Veterinary and Animal Science, Frederiksberg, Denmark, ² Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Netherlands, ³ Copenhagen University, Chemistry Institute, Østerbro, Denmark, ⁴ The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Denmark, ⁵., Department of Clinical Microbiology, Copenhagen University Hospital, Clinical Microbiology, Copenhagen, Denmark, ⁶ University of Copenhagen, Copenhagen University, Veterinary and Animal Sciences, Frederiksberg C, Denmark

In the shadow of the AMR crisis, reigniting the antibiotic pipeline has emerged as a pivotal strategy. Despite the urgent need, there has been a decrease in finding new types of natural or synthetic antibiotics over the past forty years. Of the 65 antibiotics introduced in the last two decades, only four were genuinely new pharmacological classes, whilst the remainder were merely derivatives or modifications of pre-existing compounds. This challenge arises from the need to bypass bacterial resistance, which, paradoxically, is also the target.

Inspired by a 2006 study that successfully integrated propranolol with a known drug delivery polymer, DAB-PAMAM dendrimer, for enhanced cellular uptake, we advanced this approach by conjugating the antibiotic ciprofloxacin with PAMAM dendrimers. This strategy aims to enhance the antibiotic's effectiveness by preventing its ejection from cells.

The screening results were promising as *Escherichia coli* showed MIC values of 1.25 µg/µl and *Pseudomonas aeruginosa* 1-2 µg/µl. *Staphylococcus aureus* exhibited values, oscillating between 2-4 µg/µl. MIC values, which lowered by a factor of 2 when tested in media other than MHB. The compounds did not result in cytotoxicity nor hemolysis.

An important outcome of these experiments was the insight that tackling AMR requires not only identification of suitable candidates, but also require that standardized screening methodologies are in congruence with clinical needs.

Therefore, we employed an air-liquid interface (ALI) culture set-up to mimic respiratory epithelial cells' natural environment. By introducing *P. aeruginosa*, a severe cause of respiratory infections, we sought to compare its behavior with standard lab screenings, aiming to bridge the gap between conventional lab methods and clinical needs inside the antimicrobial development pipeline.